CALIGAN PARTNERS LP
Q2 2026 Form 13-F

NEW YORK, NEW YORK
CIK 0001727492 · CRD 289887 · SEC-registered investment adviser
$2.1B Reported Value Total

CALIGAN PARTNERS reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $1,299,735,339, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
8 funds · $1.1B gross asset value
Hedge Fund: $1.1B
Source: Form ADV filed 2026-10-30
Reported value
$2.1B
Quarter over quarter
+45.9%
Holdings
25
Top-10 concentration
80.9%

Key People

Form ADV owners & control persons
David Edward Johnson
PARTNER / LIMITED PARTNER
Tiffany Crowley
CHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICER
Sarah Bates Johnson
TRUSTEE

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2026 13F record

Q2 2026 13F filing summary

Q2 2026 Form 13F portfolio summary
Period of report June 30, 2026
Filed August 14, 2026
Form 13F-HR
Reported value $2.1B
Positions 25
Change in reported value +41.5%
New positions 5
Exited positions 4
Position turnover 31.0%
Top-10 concentration 80.9%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
25 $2.1B
Q1 2026 13F
Filed May 15, 2026
24 $1.5B
Q4 2025 13F
Filed Feb 17, 2026
20 $1.2B
Q3 2025 13F
Filed Nov 14, 2025
16 $763.5M
Q2 2025 13F
Filed Aug 14, 2025
16 $520.2M
Q1 2025 13F
Filed May 15, 2025
16 $479.2M
Q4 2024 13F
Filed Feb 14, 2025
14 $394.9M
Q3 2024 13F
Filed Nov 14, 2024
12 $315.5M
Q2 2024 13F
Filed Aug 14, 2024
13 $428.0M
Q1 2024 13F
Filed May 13, 2024
12 $378.3M
Q4 2023 13F
Filed Feb 14, 2024
11 $296.5M
Q3 2023 13F
Filed Nov 14, 2023
12 $217.8M
Q2 2023 13F
Filed Aug 14, 2023
12 $177.8M
Q1 2023 13F
Filed May 15, 2023
11 $143.4M
Q4 2022 13F
Filed Feb 15, 2023
11 $120.2M

Top 20 holdings · Q2 2026

Largest Q2 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 LQDA LIQUIDIA CORPORATION $647.3M 30.45%
2 RVMD REVOLUTION MEDICINES INC $367.4M 17.28%
3 ABVX ABIVAX SA $207.6M 9.77%
4 PCVX VAXCYTE INC $127.2M 5.99%
5 EXEL EXELIXIS INC $84.5M 3.98%
6 TNGX TANGO THERAPEUTICS INC $78.2M 3.68%
7 AVTX AVALO THERAPEUTICS INC $58.5M 2.75%
8 XENE XENON PHARMACEUTICALS INC $53.7M 2.53%
9 ADMA ADMA BIOLOGICS INC $47.9M 2.25%
10 RVMD C REVOLUTION MEDICINES INC $47.2M 2.22%
11 LBRX LB PHARMACEUTICALS INC $46.7M 2.2%
12 IMCR IMMUNOCORE HLDGS PLC $43.9M 2.06%
13 VRDN VIRIDIAN THERAPEUTICS INC $40.3M 1.9%
14 VOR VOR BIOPHARMA INC $35.4M 1.67%
15 SABS SAB BIOTHERAPEUTICS INC $31.1M 1.46%
16 IVA INVENTIVA SA $30.9M 1.45%
17 AURA AURA BIOSCIENCES INC $30.5M 1.44%
18 TYRA TYRA BIOSCIENCES INC $25.8M 1.21%
19 OCUP OPUS GENETICS INC $25.0M 1.17%
20 ANIK ANIKA THERAPEUTICS INC $21.0M 0.99%

Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings